INTEGRATED DRUG DISCOVERY
We deploy significant research infrastructure and experience to support internal drug discovery programs. This infrastructure is arranged into a series of research platforms that are also available to external partners to help progress their projects. In 2022, we have started our internal discovery research in key Therapeutics areas. With close proximity to research university, we have great expansion planning in Cardiovascular & Neuro.Currently, we are in the very early stage of discovery of novel drug candidates.
We have particular skills in:
- the pharmacology of G protein-coupled receptors and the role of allostery and biased signalling in receptor pharmacology
- structure-based drug design and the use of fragment-based screening in drug discovery
- identification of optimal pharmaceutical properties for drug molecules during hit-to-lead and lead optimisation through to candidate selection
- oral and pulmonary drug delivery and the use of nanomedicines in optimised drug therapy
Neuroscience and Mental Health
The neuroscience and mental health TPA encompasses multidisciplinary approaches to unmet medical needs in psychiatry, neurodegeneration, pain, and other mental health disorders. Tackling the challenges of therapeutics at the intersection of oncology and neuroscience.
- Dementia & Neurodegeneration
- Cancer and the Brian
Cardiovascular and Metabolic Health
The cardiovascular and metabolic health TPA works to develop cardiovascular and metabolic disease therapeutics. Its expertise runs from basic research through to animal disease models and on to translational human disease. Cardiovascular and Metabolic Health encompasses medicinal chemistry, structural biology, analytical pharmacology, drug disposition, drug delivery, translational models of disease and medicines use and safety. Our commitment to research translation is evidenced by contributing to more than 30 novel drug candidates into clinical development.